JP2005517665A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005517665A5 JP2005517665A5 JP2003554640A JP2003554640A JP2005517665A5 JP 2005517665 A5 JP2005517665 A5 JP 2005517665A5 JP 2003554640 A JP2003554640 A JP 2003554640A JP 2003554640 A JP2003554640 A JP 2003554640A JP 2005517665 A5 JP2005517665 A5 JP 2005517665A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- chloro
- compound
- hept
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 31
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 229910052799 carbon Inorganic materials 0.000 claims 15
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- -1 1,2-vinylene Chemical group 0.000 claims 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 5
- 208000020084 Bone disease Diseases 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 3
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 3
- 208000005171 Dysmenorrhea Diseases 0.000 claims 2
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000005107 Premature Birth Diseases 0.000 claims 2
- 201000001880 Sexual dysfunction Diseases 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000023555 blood coagulation Effects 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 230000001066 destructive effect Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000002296 eclampsia Diseases 0.000 claims 2
- 208000012610 eosinophil disease Diseases 0.000 claims 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 2
- 208000000509 infertility Diseases 0.000 claims 2
- 230000036512 infertility Effects 0.000 claims 2
- 231100000535 infertility Toxicity 0.000 claims 2
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 201000011461 pre-eclampsia Diseases 0.000 claims 2
- 230000001850 reproductive effect Effects 0.000 claims 2
- 231100000872 sexual dysfunction Toxicity 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 2
- OEUCKFCCMTUKIN-ARSSERGMSA-N (z)-7-[(2s,3r)-1-[4-(1-butylcyclobutyl)-4-hydroxybutyl]-3-chloropyrrolidin-2-yl]hept-5-enoic acid Chemical compound N1([C@H]([C@H](Cl)CC1)C\C=C/CCCC(O)=O)CCCC(O)C1(CCCC)CCC1 OEUCKFCCMTUKIN-ARSSERGMSA-N 0.000 claims 1
- WORSKZLXWOPPRT-OBOIRMAPSA-N (z)-7-[(2s,3r)-3-chloro-1-(4-hydroxynonyl)pyrrolidin-2-yl]hept-5-enoic acid Chemical compound CCCCCC(O)CCCN1CC[C@@H](Cl)[C@@H]1C\C=C/CCCC(O)=O WORSKZLXWOPPRT-OBOIRMAPSA-N 0.000 claims 1
- ZUBWYRGWYZPOJG-ZYBDUAIHSA-N (z)-7-[(2s,3r)-3-chloro-1-[4-(1-ethylcyclobutyl)-4-hydroxybutyl]pyrrolidin-2-yl]hept-5-enoic acid Chemical compound N1([C@H]([C@H](Cl)CC1)C\C=C/CCCC(O)=O)CCCC(O)C1(CC)CCC1 ZUBWYRGWYZPOJG-ZYBDUAIHSA-N 0.000 claims 1
- WQWYUHGVECHFML-BHQIHCQQSA-N (z)-7-[1-(3-hydroxy-4-phenylbutyl)-3-oxopyrrolidin-2-yl]hept-5-enoic acid Chemical compound C=1C=CC=CC=1CC(O)CCN1CCC(=O)C1C\C=C/CCCC(O)=O WQWYUHGVECHFML-BHQIHCQQSA-N 0.000 claims 1
- JJDJAQURCDMVEZ-BHQIHCQQSA-N (z)-7-[1-[3-hydroxy-3-(1-phenylcyclopropyl)propyl]-3-oxopyrrolidin-2-yl]hept-5-enoic acid Chemical compound C1CC1(C=1C=CC=CC=1)C(O)CCN1CCC(=O)C1C\C=C/CCCC(O)=O JJDJAQURCDMVEZ-BHQIHCQQSA-N 0.000 claims 1
- MPDFVYXVHHWOBS-RQOWECAXSA-N (z)-7-[1-[3-hydroxy-4-(3-methylphenyl)butyl]-3-oxopyrrolidin-2-yl]hept-5-enoic acid Chemical compound CC1=CC=CC(CC(O)CCN2C(C(=O)CC2)C\C=C/CCCC(O)=O)=C1 MPDFVYXVHHWOBS-RQOWECAXSA-N 0.000 claims 1
- RNAWKKRPMPVZDS-JUODMZLFSA-N 4-[2-[(2s,3r)-3-chloro-1-(4-hydroxynonyl)pyrrolidin-2-yl]ethyl]benzoic acid Chemical compound CCCCCC(O)CCCN1CC[C@@H](Cl)[C@@H]1CCC1=CC=C(C(O)=O)C=C1 RNAWKKRPMPVZDS-JUODMZLFSA-N 0.000 claims 1
- ARUOZFXJYVGMEZ-UHFFFAOYSA-N 4-[2-[1-[4-(1-butylcyclobutyl)-4-hydroxybutyl]-3-chloropyrrolidin-2-yl]ethyl]benzoic acid Chemical compound C1CC(Cl)C(CCC=2C=CC(=CC=2)C(O)=O)N1CCCC(O)C1(CCCC)CCC1 ARUOZFXJYVGMEZ-UHFFFAOYSA-N 0.000 claims 1
- YERPWZWEOZXLHC-UHFFFAOYSA-N 4-[2-[3-chloro-1-(3-hydroxyoctyl)pyrrolidin-2-yl]ethyl]benzoic acid Chemical compound CCCCCC(O)CCN1CCC(Cl)C1CCC1=CC=C(C(O)=O)C=C1 YERPWZWEOZXLHC-UHFFFAOYSA-N 0.000 claims 1
- RNAWKKRPMPVZDS-QNGMFEMESA-N 4-[2-[3-chloro-1-[(4r)-4-hydroxynonyl]pyrrolidin-2-yl]ethyl]benzoic acid Chemical compound CCCCC[C@@H](O)CCCN1CCC(Cl)C1CCC1=CC=C(C(O)=O)C=C1 RNAWKKRPMPVZDS-QNGMFEMESA-N 0.000 claims 1
- UVDLBZOMZJQSHO-UHFFFAOYSA-N 4-[[3-chloro-1-(3-hydroxyoctyl)pyrrolidin-2-yl]methoxy]benzoic acid Chemical compound CCCCCC(O)CCN1CCC(Cl)C1COC1=CC=C(C(O)=O)C=C1 UVDLBZOMZJQSHO-UHFFFAOYSA-N 0.000 claims 1
- DJHHWYCXDBZACW-UHFFFAOYSA-N 5-[[3-chloro-1-(3-hydroxyoctyl)pyrrolidin-2-yl]methoxymethyl]furan-2-carboxylic acid Chemical compound CCCCCC(O)CCN1CCC(Cl)C1COCC1=CC=C(C(O)=O)O1 DJHHWYCXDBZACW-UHFFFAOYSA-N 0.000 claims 1
- WORSKZLXWOPPRT-OMKBGSMGSA-N 7-[(2r,3r)-3-chloro-1-(4-hydroxynonyl)pyrrolidin-2-yl]hept-5-enoic acid Chemical compound CCCCCC(O)CCCN1CC[C@@H](Cl)[C@H]1CC=CCCCC(O)=O WORSKZLXWOPPRT-OMKBGSMGSA-N 0.000 claims 1
- UXFUSNXQQSROQH-GVULCQSLSA-N 7-[(3R)-3-chloro-1-[(E)-4-hydroxynon-2-enyl]pyrrolidin-2-yl]hept-5-enoic acid Chemical compound CCCCCC(O)\C=C\CN1CC[C@@H](Cl)C1CC=CCCCC(O)=O UXFUSNXQQSROQH-GVULCQSLSA-N 0.000 claims 1
- UXFUSNXQQSROQH-PZXDZYTHSA-N 7-[(3R)-3-chloro-1-[(Z)-4-hydroxynon-2-enyl]pyrrolidin-2-yl]hept-5-enoic acid Chemical compound CCCCCC(O)\C=C/CN1CC[C@@H](Cl)C1CC=CCCCC(O)=O UXFUSNXQQSROQH-PZXDZYTHSA-N 0.000 claims 1
- JGHWPUQGDCHPGD-UHFFFAOYSA-N 7-[1-[4-[1-(cyclopropylmethyl)cyclobutyl]-4-hydroxybutyl]-3-oxopyrrolidin-2-yl]heptanoic acid Chemical compound C1CCC1(CC1CC1)C(O)CCCN1CCC(=O)C1CCCCCCC(O)=O JGHWPUQGDCHPGD-UHFFFAOYSA-N 0.000 claims 1
- XPFQHSTXMOFOHN-UHFFFAOYSA-N 7-[3-chloro-1-[4-[1-(cyclopropylmethyl)cyclobutyl]-4-hydroxybutyl]pyrrolidin-2-yl]hept-5-enoic acid Chemical compound C1CCC1(CC1CC1)C(O)CCCN1CCC(Cl)C1CC=CCCCC(O)=O XPFQHSTXMOFOHN-UHFFFAOYSA-N 0.000 claims 1
- ILNIGKAAKHUDLX-UHFFFAOYSA-N 7-[3-chloro-1-[4-hydroxy-4-(1-propylcyclobutyl)butyl]pyrrolidin-2-yl]hept-5-enoic acid Chemical compound C1CC(Cl)C(CC=CCCCC(O)=O)N1CCCC(O)C1(CCC)CCC1 ILNIGKAAKHUDLX-UHFFFAOYSA-N 0.000 claims 1
- 206010036590 Premature baby Diseases 0.000 claims 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 1
- FKCMADOPPWWGNZ-YUMQZZPRSA-N [(2r)-1-[(2s)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl]boronic acid Chemical class CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O FKCMADOPPWWGNZ-YUMQZZPRSA-N 0.000 claims 1
- 230000001548 androgenic effect Effects 0.000 claims 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- UVMCLYANNMGMGM-QRWMCTBCSA-N methyl 7-[(2r)-1-(3-hydroxyoctyl)-3-oxopyrrolidin-2-yl]hept-5-enoate Chemical compound CCCCCC(O)CCN1CCC(=O)[C@H]1CC=CCCCC(=O)OC UVMCLYANNMGMGM-QRWMCTBCSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34262001P | 2001-12-20 | 2001-12-20 | |
| PCT/EP2002/014593 WO2003053923A2 (en) | 2001-12-20 | 2002-12-19 | Pyrrolidine derivatives as prostaglandin modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005517665A JP2005517665A (ja) | 2005-06-16 |
| JP2005517665A5 true JP2005517665A5 (https=) | 2006-02-09 |
| JP4554931B2 JP4554931B2 (ja) | 2010-09-29 |
Family
ID=23342570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003554640A Expired - Fee Related JP4554931B2 (ja) | 2001-12-20 | 2002-12-19 | プロスタグランジン調節物質としてのピロリジン誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7335680B2 (https=) |
| EP (1) | EP1458679B1 (https=) |
| JP (1) | JP4554931B2 (https=) |
| AT (1) | ATE455758T1 (https=) |
| AU (2) | AU2002358772B2 (https=) |
| CA (1) | CA2469075C (https=) |
| DE (1) | DE60235198D1 (https=) |
| ES (1) | ES2337887T3 (https=) |
| IL (2) | IL162602A0 (https=) |
| WO (1) | WO2003053923A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60235198D1 (de) * | 2001-12-20 | 2010-03-11 | Merck Serono Sa Coinsins | Pyrrolidin-derivatie als prostaglandin-modulatoren |
| ES2584606T3 (es) | 2002-10-10 | 2016-09-28 | Ono Pharmaceutical Co., Ltd. | Microesferas que comprenden ONO-1301 |
| KR100843244B1 (ko) | 2007-04-19 | 2008-07-02 | 삼성전자주식회사 | 반도체 소자 및 그 제조 방법 |
| WO2006052893A2 (en) | 2004-11-08 | 2006-05-18 | Allergan, Inc. | Substituted pyrrolidone compounds as ep4 agonists |
| US7893107B2 (en) | 2005-11-30 | 2011-02-22 | Allergan, Inc. | Therapeutic methods using prostaglandin EP4 agonist components |
| US7557095B2 (en) * | 2006-05-12 | 2009-07-07 | Allergan, Inc. | Therapeutic compounds |
| US7550448B2 (en) * | 2006-05-24 | 2009-06-23 | Allergan, Inc. | Therapeutic compounds |
| EP2147672A4 (en) | 2007-05-08 | 2011-11-02 | Nat University Corp Hamamatsu University School Of Medicine | CYTOTOXIC T CELL ACTIVATOR WITH AN EP4 AGONIST |
| SI2155733T1 (sl) * | 2007-05-23 | 2012-12-31 | Allergan, Inc | Ciklični laktami za zdravljenje glavkoma ali zvišanega očesnega tlaka |
| US7964596B2 (en) * | 2008-03-07 | 2011-06-21 | Allergan, Inc. | Therapeutic compounds |
| EP2149551A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors |
| EP2149554A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma Aktiengesellschaft | Indolylamide als Modulatoren des EP2-Rezeptors |
| EP2149552A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors |
| GEP20125607B (en) * | 2008-11-10 | 2012-08-10 | Pfizer Ltd | Pyrrolidines |
| JPWO2010087425A1 (ja) | 2009-01-30 | 2012-08-02 | 国立大学法人京都大学 | 前立腺癌の進行抑制剤および進行抑制方法 |
| TW201326154A (zh) | 2011-11-28 | 2013-07-01 | 拜耳知識產權公司 | 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑 |
| ES2733998T3 (es) | 2012-10-29 | 2019-12-03 | Cardio Incorporated | Agente terapéutico específico de enfermedad pulmonar |
| US9968716B2 (en) | 2013-10-15 | 2018-05-15 | Ono Pharmaceutical Co., Ltd. | Drug-eluting stent graft |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3873566A (en) * | 1973-02-28 | 1975-03-25 | Du Pont | 3-Pyrazolidinones and pyrazolidines |
| DE2451160A1 (de) * | 1973-10-30 | 1975-05-07 | Du Pont | 3-pyrazolidinone und pyrazolidine |
| US3976660A (en) * | 1974-08-15 | 1976-08-24 | E. R. Squibb & Sons, Inc. | Pyrrolidine derivatives |
| DE2527989A1 (de) | 1975-06-24 | 1977-01-27 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
| US4033989A (en) | 1975-09-17 | 1977-07-05 | The Upjohn Company | 9-Deoxy-PGF2 Analogs |
| US4003911A (en) * | 1975-09-26 | 1977-01-18 | E. I. Du Pont De Nemours And Company | Selected 3-pyrrolidinones and 2,4-pyrrolidindiones |
| US4090019A (en) | 1976-05-10 | 1978-05-16 | Minnesota Mining And Manufacturing Company | Geminal prostaglandin analogs |
| US4211876A (en) * | 1979-06-13 | 1980-07-08 | E. I. Du Pont De Nemours And Company | 3-Pyrazolidinone carboxamides |
| US4753945A (en) | 1986-02-19 | 1988-06-28 | Eye Research Institute Of Retina Foundation | Stimulation of tear secretion with phosphodiesterase inhibitors |
| US5091431A (en) | 1988-02-08 | 1992-02-25 | Schering Corporation | Phosphodiesterase inhibitors |
| US5010086A (en) | 1990-02-28 | 1991-04-23 | Sterling Drug Inc. | Imidazopyridines, compositions and use |
| GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| GB9119704D0 (en) | 1991-09-14 | 1991-10-30 | Pfizer Ltd | Therapeutic agents |
| GB9121028D0 (en) | 1991-10-03 | 1991-11-13 | Pfizer Ltd | Therapeutic agents |
| GB9126260D0 (en) | 1991-12-11 | 1992-02-12 | Pfizer Ltd | Therapeutic agents |
| GB9213623D0 (en) | 1992-06-26 | 1992-08-12 | Pfizer Ltd | Therapeutic agents |
| GB9218322D0 (en) | 1992-08-28 | 1992-10-14 | Pfizer Ltd | Therapeutic agents |
| US5605814A (en) | 1993-08-31 | 1997-02-25 | Merck Frosst Canada Inc. | DNA encoding human prostaglandin receptor EP2 |
| US6143746A (en) | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
| GB9514465D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
| GB9514160D0 (en) | 1994-07-25 | 1995-09-13 | Zeneca Ltd | Aromatic compounds |
| GB9417532D0 (en) | 1994-08-31 | 1994-10-19 | Zeneca Ltd | Aromatic compounds |
| GB9423911D0 (en) | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
| TW434240B (en) | 1995-06-20 | 2001-05-16 | Zeneca Ltd | Aromatic compounds, preparation thereof and pharmaceutical composition comprising same |
| TW502026B (en) | 1995-06-20 | 2002-09-11 | Zeneca Ltd | Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates |
| EP0752421B1 (en) | 1995-07-07 | 2005-10-12 | AstraZeneca AB | Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists |
| GB9514464D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
| GB9514473D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
| ES2175404T3 (es) | 1996-05-10 | 2002-11-16 | Icos Corp | Derivados de carbolina. |
| EP0941221B1 (en) | 1996-11-20 | 2003-02-26 | ALTANA Pharma AG | Substituted dihydrobenzofurans as pde inhibitors |
| UA59384C2 (uk) | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
| AT404730B (de) * | 1997-04-07 | 1999-02-25 | Holderchem Ag | Acryl-copolymere und polymerzusammensetzungen sowie deren verwendung als additive oder beimischungen zur verbesserung der eigenschaften von dispersionen und baustoffen |
| US6043252A (en) | 1997-05-05 | 2000-03-28 | Icos Corporation | Carboline derivatives |
| JP2001510827A (ja) | 1997-07-25 | 2001-08-07 | ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | 置換６−フェニルフェナントリジン |
| US6006735A (en) | 1997-09-12 | 1999-12-28 | Park Industries, Inc. | Automated stoneworking system and method |
| US6156753A (en) | 1997-10-28 | 2000-12-05 | Vivus, Inc. | Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| US6127363A (en) | 1997-10-28 | 2000-10-03 | Vivus, Inc. | Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| GB9725953D0 (en) | 1997-12-08 | 1998-02-04 | Pfizer Ltd | Compounds useful in therapy |
| US6211197B1 (en) | 1998-10-07 | 2001-04-03 | Merck Frosst Canada & Co. | Prostaglandin receptor ligands |
| GB9822238D0 (en) | 1998-10-12 | 1998-12-09 | Pfizer Ltd | Process for preparation of pyrazolo[4,3-D]pyrimidin-7-ones and intermediates thereof |
| GEP20043203B (en) * | 1999-12-22 | 2004-03-25 | Pfizer Prod Inc | EP4 Receptor Selective Agonists in the Treatment of Osteoporosis |
| CA2451392A1 (en) * | 2001-07-16 | 2003-01-30 | F. Hoffmann-La Roche Ag | Prostaglandin analogues as ep4 receptor agonists |
| DE60235198D1 (de) * | 2001-12-20 | 2010-03-11 | Merck Serono Sa Coinsins | Pyrrolidin-derivatie als prostaglandin-modulatoren |
-
2002
- 2002-12-19 DE DE60235198T patent/DE60235198D1/de not_active Expired - Lifetime
- 2002-12-19 ES ES02793091T patent/ES2337887T3/es not_active Expired - Lifetime
- 2002-12-19 IL IL16260202A patent/IL162602A0/xx unknown
- 2002-12-19 US US10/499,346 patent/US7335680B2/en not_active Expired - Fee Related
- 2002-12-19 AU AU2002358772A patent/AU2002358772B2/en not_active Ceased
- 2002-12-19 JP JP2003554640A patent/JP4554931B2/ja not_active Expired - Fee Related
- 2002-12-19 WO PCT/EP2002/014593 patent/WO2003053923A2/en not_active Ceased
- 2002-12-19 AT AT02793091T patent/ATE455758T1/de not_active IP Right Cessation
- 2002-12-19 CA CA2469075A patent/CA2469075C/en not_active Expired - Fee Related
- 2002-12-19 EP EP02793091A patent/EP1458679B1/en not_active Expired - Lifetime
-
2004
- 2004-06-17 IL IL162602A patent/IL162602A/en not_active IP Right Cessation
-
2007
- 2007-11-21 US US11/943,684 patent/US7635713B2/en not_active Expired - Fee Related
-
2009
- 2009-02-19 AU AU2009200663A patent/AU2009200663B2/en not_active Ceased
- 2009-08-03 US US12/534,292 patent/US8058305B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005517665A5 (https=) | ||
| CA2206776C (en) | N-sulfonylindoline derivatives carrying an amide functional group, their preparation and the pharmaceutical compositions in which they are present | |
| ES2268327T3 (es) | Uso de un selectivo de un receptor de ep4 para el tratamiento de enfermedades. | |
| RU2306309C2 (ru) | Производное 8-азапростагландина, фармацевтическая композиция, агент для профилактики заболеваний | |
| CN1188422C (zh) | 钙(3s)四氢－3－呋喃基(1s,2r)－3－[[(4－氨基苯基)磺酰基](异丁基)氨基]－1－苯甲基－2－(膦酰氧基]丙基氨基甲酸酯 | |
| US8501793B2 (en) | Blood flow promoters for cauda equina tissues | |
| JP2005509632A5 (https=) | ||
| JP5399237B2 (ja) | ヒトパピローマウイルス阻害剤としてのピペリジン誘導体 | |
| CA2469075A1 (en) | Pyrrolidine derivatives as prostaglandin modulators | |
| JP2002527419A (ja) | Ｇｓｋ−３阻害物質としてのピロール−２，５−ジオン類 | |
| WO2004031118A1 (ja) | Ｌｐａ受容体拮抗剤 | |
| JP2007530694A5 (https=) | ||
| JPWO2003009872A1 (ja) | Ｅｐ▲下４▼アゴニストを有効成分とする骨量低下疾患の治療剤 | |
| JP2009534398A5 (https=) | ||
| JP2011168606A (ja) | 下部尿路症状を治療するα−２−δリガンド | |
| JP2004520302A5 (https=) | ||
| HUT73806A (en) | Pyrrolidine and thiazolidine derivatives, process for their preparation and pharmaceutical compositions containing them | |
| JP2010511631A5 (https=) | ||
| JP2007522135A5 (https=) | ||
| JP2006515004A5 (https=) | ||
| JP5907077B2 (ja) | 二環式化合物およびその医薬用途 | |
| JP2007531766A5 (https=) | ||
| JP2018502911A5 (https=) | ||
| RU2007116037A (ru) | Новая кристаллическая форма (3-циано-1н-индол-7-ил)-[4-(4-фторфенэтил)пиперазин-1-ил]метанона, гидрохлорида | |
| CN1260798A (zh) | 具有5－羟色胺－2受体拮抗作用和α1－阻断作用的吡咯噻嗪和吡咯硫杂吖庚因化合物 |